Toxicity and antitumor activity after single and repetitive therapy in patients with 131I-MIP-1095 in patients with metastatic prostate cancer

Trial Profile

Toxicity and antitumor activity after single and repetitive therapy in patients with 131I-MIP-1095 in patients with metastatic prostate cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs MIP 1095-I-131 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top